Second, breast cancer has benefited from advancements in personalized medicine, where treatments are tailored based on specific genetic markers such as HER2 status, which can predict responsiveness to certain targeted therapies in addition to conventional chemotherapeutic agents. This evidence concerns the gene ERBB2 and breast cancer.